Open AccessComparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis
Author(s) -
Ran Pan,
Xiaolun Wang,
Min Su,
Jaydeep Das,
Manik Kalra,
Zhidong Wang
Publication year - 2021
Publication title -
chinese medical journal/chinese medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.537
H-Index - 63
eISSN - 2542-5641
pISSN - 0366-6999
DOI - 10.1097/cm9.0000000000001817
Subject(s) - secukinumab , medicine , adalimumab , psoriasis area and severity index , psoriasis , plaque psoriasis , infliximab , confidence interval , placebo , randomized controlled trial , dermatology , meta analysis , gastroenterology , disease , psoriatic arthritis , pathology , alternative medicine
Psoriasis is a common, chronic, immune-mediated inflammatory skin disease with increased epidermal proliferation. The objective of this review was to systematically identify the evidence and perform a network meta-analysis (NMA) to estimate the relative efficacy of secukinumab (SEC) against adalimumab (ADA) and infliximab (INF) for the treatment of moderate-to-severe plaque psoriasis.